Metastatic Malignant Neoplasm
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Metastatic Malignant Neoplasm is an early-stage landscape with 9 programs across 8 companies. The most active players are Glaxo Dba Glaxosmithkline, Merck & Co., Avyxa. 5 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Glaxo Dba Glaxosmithkline
1 program
Merck & Co.
1 program
Avyxa
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
UroGen Pharma Ltd.
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
78%
Small molecule
7 of 9 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)